Online citations, reference lists, and bibliographies.

The Effects Of Metformin On The Survival Of Colorectal Cancer Patients With Diabetes Mellitus.

Jin Ha Lee, Tae Il Kim, Soung Min Jeon, Sung Pil Hong, Jae Hee Cheon, Won Ho Kim
Published 2012 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Metformin use has been associated with decreased cancer risk and mortality. However, the effects of metformin on clinical outcomes of colorectal cancer (CRC) are not defined. This study aimed to evaluate the association between metformin use and mortality of CRC in diabetic patients. We identified 595 patients who were diagnosed both CRC and diabetes mellitus. Patients were compared by two groups; 258 diabetic patients taking metformin and 337 diabetic patients not taking metformin. Patient's demographics, clinical characteristics, overall mortality and CRC-specific mortality were analyzed. After a median follow-up of 41 months, there were 71 total deaths (27.5%) and 55 CRC-specific deaths (21.3%) among 258 patients who used metformin, compared with 136 total deaths (40.4%) and 104 CRC-specific deaths (30.9%) among 337 patients who did not use metformin. Metformin use was associated with decreased overall mortality (p = 0.018) and CRC-specific mortality (p = 0.042) by univariate analysis. After adjustment for clinically relevant factors, metformin use showed lower risk of overall mortality (HR, 0.66; 95% CI 0.476-0.923; p = 0.015) and CRC-specific mortality (HR, 0.66; 95% CI 0.45-0.975; p = 0.037) in CRC patients with diabetes. Metformin use in CRC patients with diabetes is associated with lower risk of CRC-specific and overall mortality.
This paper references
10.1016/S1470-2045(04)01509-8
Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists
Christian Grommes (2004)
10.1080/13813450802008455
Type 2 diabetes mellitus as risk factor for colorectal cancer.
Jutta M. Berster (2008)
10.1053/j.gastro.2004.07.011
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients.
Yu-Xiao Yang (2004)
10.1158/0008-5472.CAN-06-1500
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.
Mahvash Zakikhani (2006)
10.1038/nrc2536
Insulin and insulin-like growth factor signalling in neoplasia
Michael D Pollak (2008)
10.4161/cc.8.1.7499
The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells
Alejandro Vázquez-Martín (2009)
10.1007/s10549-008-0016-3
Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model
Sirwan M. Hadad (2008)
10.2337/dc09-1380
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Gijs W D Landman (2009)
10.1007/s00535-010-0310-9
Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs
Toshikatsu Okumura (2010)
10.2337/diacare.29.02.06.dc05-1558
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Samantha L. Bowker (2006)
10.1007/s10549-008-9916-5
Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model
Kathryn N. Phoenix (2008)
10.1053/j.gastro.2010.06.072
Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men.
Peter T. Campbell (2010)
10.1007/s00125-010-1750-8
Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure
Samantha L. Bowker (2010)
10.1136/bmj.38415.708634.F7
Metformin and reduced risk of cancer in diabetic patients
Josie M. M. Evans (2005)
10.1093/jnci/dji375
Diabetes mellitus and risk of colorectal cancer: a meta-analysis.
Susanna C. Larsson (2005)
10.1158/0008-5472.CAN-09-2994
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.
Heather Hirsch (2009)
10.1016/j.ceb.2005.09.009
Growing roles for the mTOR pathway.
Dos D Sarbassov (2005)
10.4149/neo_2009_03_269
Metformin in chemically-induced mammary carcinogenesis in rats.
Bianka Bojková (2009)
10.1007/s10620-009-0944-8
Colorectal Cancer Outcomes, Recurrence, and Complications in Persons With and Without Diabetes Mellitus: A Systematic Review and Meta-Analysis
Kelly B. Stein (2009)
10.1126/science.1120781
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Reuben J. Shaw (2005)
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists.
Christian Grommes (2004)
10.1677/erc.1.01182
Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
J-R Weng (2006)
10.1677/ERC-09-0252
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.
Carolyn Algire (2010)
10.4161/cc.8.10.8406
Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells
Cristina Oliveras-Ferraros (2009)
10.1042/CS20090399
Insulin resistance and hyperinsulinaemia in the development and progression of cancer
Ian F. Godsland (2009)
10.1158/0008-5472.CAN-09-2782
Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.
Issam Ben Sahra (2010)
Genome - wide inhibitory impact of the AMPK activator metformin on [ kinesins , tubulins , histones , auroras and pololike kinases ] Mphase
C Oliveras-Ferraros (2010)
10.3322/caac.20073
Cancer statistics, 2010.
Ahmedin Jemal (2010)
C an ce r T he ra py Lee et al
I Ben Sahra (2011)
10.1007/s00125-009-1440-6
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Craig J Currie (2009)
10.1111/j.1349-7006.2008.00933.x
Metformin suppresses intestinal polyp growth in ApcMin/+ mice.
Ayako Tomimoto (2008)
10.1097/01.cad.0000173476.67239.3b
PI3K/Akt/mTOR pathway as a target for cancer therapy
Daniel Morgensztern (2005)
10.1158/1078-0432.CCR-09-2229
Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer
Enrique Rozengurt (2010)
10.1016/S0140-6736(00)02261-3
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
Hany Elsaleh (2000)
10.1002/mc.20637
Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.
Kunihiro Hosono (2010)



This paper is referenced by
10.1155/2019/6527457
Impact of Metabolic Syndrome Diagnosis and Its Treatment on Survival of Colorectal Cancer Patients
Rose Ngozi Mafiana (2019)
10.3748/wjg.v23.i28.5196
Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients
Jung Won Park (2017)
Chemopreventive drugs : Mechanisms via inhibition of cancer stem cells in colorectal cancer
Tae Il Kim (2014)
10.1245/s10434-015-5028-8
Metformin Increases Overall Survival in Patients with Diabetes Undergoing Surgery for Colorectal Cancer
Tina Fransgaard (2015)
10.1158/1055-9965.EPI-17-0424
A Cohort Study of Metformin and Colorectal Cancer Risk among Patients with Diabetes Mellitus
Marie C Bradley (2018)
10.1002/ijc.32989
Postdiagnostic Metformin Use and Survival of Patients With Colorectal Cancer: A Nationwide Cohort study.
Wen-Kuan Huang (2020)
10.1530/JME-12-0007
Metformin in cancer: translational challenges.
Ryan J. O. Dowling (2012)
10.1007/s13277-014-1676-8
Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery
Mihaela Monica Aldea (2014)
10.6016/slovmedjour.v86i3-4.1503
Metformin: from mechanisms of action to advanced clinical use
Miodrag Janić (2017)
10.1158/1055-9965.EPI-16-0312
Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer
Jessica K. Paulus (2016)
Неоднозначность данных об эффективности метформина как средства, снижающего массу тела и предотвращающего опухолевый рост: причины и следствия
Lew M Berstein (2012)
10.1097/MD.0000000000003528
The Effect of Diabetes Mellitus on Lung Cancer Prognosis
Linhai Zhu (2016)
10.18632/oncotarget.14688
Prognostic role of metformin intake in diabetic patients with colorectal cancer: An updated qualitative evidence of cohort studies
Lili Du (2017)
10.1007/s00384-020-03539-5
Effect of metformin on the mortality of colorectal cancer patients with T2DM: meta-analysis of sex differences
Yunzi Wang (2020)
10.1097/DCR.0000000000001624
Survival Benefit for Metformin Through Better Tumor Response by Neoadjuvant Concurrent Chemoradiotherapy in Rectal Cancer
Jung Kim (2020)
10.4239/wjd.v3.i4.60
Diabetes, insulin and cancer risk.
Xi-lin Yang (2012)
10.1155/2013/636927
Risk of Cancer in Diabetes: The Effect of Metformin
Mojtaba Malek (2013)
10.1155/2017/5063239
Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis
Fanqiang Meng (2017)
10.3390/pharmaceutics12040301
Phenformin Attenuates Renal Injury in Unilateral Ureteral Obstructed Mice without Affecting Immune Cell Infiltration
Mikkel Ø Nørgård (2020)
10.1007/BF03345423
Does use of metformin protect against cancer in Type 2 diabetes mellitus?
Simona Bo (2012)
10.1371/journal.pone.0084369
Metformin: A Potential Therapeutic Agent for Recurrent Colon Cancer
Pratima Nangia-Makker (2014)
10.1007/s11888-013-0198-x
Type II Diabetes, Metformin Use, and Colorectal Neoplasia: Mechanisms of Action and Implications for Future Research
Jin ha Lee (2013)
The investigation of the effects of Metformin in Thyroid Cancer
Safar Kheder (2018)
10.1016/j.cmet.2016.09.006
Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin.
Dan Y. Gui (2016)
10.1371/journal.pone.0219944
A more physiological approach to lipid metabolism alterations in cancer: CRC-like organoids assessment
Silvia Cruz-Gil (2019)
10.1055/a-0621-8830
Metformin and Colorectal Cancer - A Systematic Review.
Jarek Kobiela (2018)
10.1016/J.ANDO.2013.02.009
Quels bénéfices antitumoraux attendre de la metformine
Emmanuel Beck (2013)
10.1002/bjs.9229
Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer.
Kirstin M J De Bruijn (2013)
10.1016/j.canep.2013.12.003
Metformin exposure and disseminated disease in patients with colorectal cancer.
Susan Spillane (2014)
10.1634/theoncologist.2016-0153
Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)
Preet Paul Singh (2016)
10.1038/s41598-017-18762-4
Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism
Jae Rin Kim (2017)
10.1371/journal.pone.0081264
Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients
Yan-fei Zhang (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar